Laidlaw analyst Yale Jen initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $19 price target Nuvectis is an early to mid-clinical stage oncology emphasized biotech company that focuses on two novel and first-in-class therapies, the analyst tells investors in a research note. The firm says the company’s lead product, NXP900, could find potential use as monotherapy for treating multiple squamous carcinomas.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis announces new publication of research study on NXP900, osimertinib
- Nuvectis Pharma Reports 2024 Financial Results and Progress
- Nuvectis Pharma initiated with a Buy at Lucid Capital
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position
- Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright